# <sup>1</sup> Efficacy and Safety of Albendazole 400 mg for 30 Days in

- 2 Adults Patients with Low Loa loa Microfilaremia: A Non-
- <sup>3</sup> Inferiority Randomized Controlled Trial Compared to
- 4 Ivermectin
- 5

# 6 Albendazole 400 mg for 30 days in Adult Patients with

7 Low Loa loa Microfilaremia

8

- 9 Luccheri Ndong Akomezoghe<sup>1,2</sup>, Noé Patrick M'Bondoukwé<sup>1,2,3</sup>, Denise Patricia Mawili Mboumba<sup>1,2,3</sup>, Jacques
- 10 Mari Ndong Ngomo<sup>1,2,3</sup>, Moutombi Ditombi Bridy Chesli<sup>1,2,3</sup>, Hadry Roger Sibi Matotou<sup>1,3</sup>, Valentin Migueba<sup>1,3</sup>,
- 11 Marielle Karine Bouyou Akotet<sup>1,2,3\*</sup>
- 12
- 13 <sup>1</sup> Department of Parasitology-Mycology-Tropical Medicine, Faculty of Medicine, Université des Sciences de la
- 14 Santé, BP 4009, Libreville Gabon
- <sup>2</sup> Unité Mixte de Recherche sur les Agents Infectieux et leur Pathologie (UMRAIP), Université des Sciences de la
- 16 Santé, Owendo, Gabon
- 17 <sup>3</sup> Centre de REcherche biomédicale en pathogènes Infectieux et Pathologies Associées (CREIPA), Libreville,
- 18 Gabon
- 19
- 20 \*Corresponding author
- 21 Email: <u>mariellebouyou@gmail.com</u> (MKBA)

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 23 Abstract

#### 24 Background

Loa loa infection is endemic in central African countries like Gabon and in West Africa. Treatment typically
involves the use of ivermectin and albendazole, with albendazole often used to reduce microfilaremia in
individuals with high microfilaremia before administering ivermectin. This study aims to evaluate the efficacy and
safety of albendazole in patients with low microfilaremia.

#### 29 Methodology and principal findings

30 The study was conducted from November 7 to April 1 across 31 villages in the Woleu-Ntem province of northern 31 Gabon. Following a questionnaire, venous blood was collected in EDTA tubes for Loa loa diagnosis. Eligible 32 individuals were randomized into two treatment groups and followed for 30 days. One group received daily 33 albendazole tablets (400 mg), while the other received a single dose of ivermectin (200µg/kg). The study reported 34 a 33.0% prevalence of Loa loa infection in northern Gabon. In the per-protocol analysis, the mean microfilaremia 35 decreased significantly by 82.3% and 90.4% in the ALB and IVM groups, respectively (p< 0.001). The risk 36 difference between the treatments was 8.1% [95% CI: 16.8 ; -0.6%]. For the intention-to-treat analysis, the mean 37 microfilaremia decreased significantly by 82.4% and 90.8% in the ALB and IVM groups, respectively (p < 0.001), 38 with a risk difference of 8.4% [95% CI: 16.2; 0.6%]. Eosinophil rates decreased by day 30 in both groups, though 39 not significantly different (p>0.05).

#### 40 Conclusions/Significance

41 The prevalence of *Loa loa* infection (33.05%) is notably high in northern Gabon. Albendazole demonstrated 42 microfilaricidal activity in individuals with low *Loa loa* microfilaremia. However, its efficacy appears inferior to 43 that of ivermectin and seems to diminish at very low microfilarial loads.

44

### 45 Author summary

*Loa loa* infection is endemic in central African countries, including Gabon, and across West Africa. Despite the
absence of specific treatments developed for *Loa loa*, current therapeutic approaches predominantly rely on
diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB). Although ALB is more readily available,

- 49 it is typically reserved for patients with high microfilaremia due to potential severe adverse effects following
- 50 treatment with IVM. This study aimed to evaluate the efficacy and safety of ALB as an alternative treatment for
- 51 patients with low microfilaremia compared to IVM. The findings suggest that ALB could serve as a viable
- 52 alternative for the treatment of microfilaremic loiasis. Moreover, ALB treatment demonstrated adequate clinical
- 53 efficacy and safety comparable to that of IVM .

54

# 56 Introduction

Loiasis is a neglected filarial parasitic disease endemic to West and Central Africa [1]. It is caused by the *Loa loa* worm, with adult worms residing in the skin or intermuscular fascia and microfilariae found in the blood. Over 10 million people are estimated to be carriers of this parasite [2]. Common clinical manifestations of loiasis include Calabar swelling, eyeworm, subconjunctival migration, subcutaneous crawling, and pruritus [3,4]. There are no specific drugs **developed** exclusively for *Loa loa*; however, current treatment strategies primarily rely on the use of diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB).

63 The World Health Organization (WHO) has implemented the Community-Directed Treatment with Ivermectin 64 to eradicate onchocerciasis and lymphatic filariasis [5,6]. However, in regions where (CDTI) strategy 65 onchocerciasis coexists with loiasis, CDTI poses a risk to individuals with Loa loa hypermicrofilaremia, defined 66 as a parasite density higher that 8,000 microfilariae per milliliter of blood (mf/mL). Patients with this condition 67 may experience severe and/or serious adverse events (SAEs) following IVM treatment, making areas with 68 onchocerciasis-loiasis co-endemicity ineligible for CDTI [7,8]. In areas where onchocerciasis is hypoendemic, 69 such as Gabon, a Test and Treat strategy is considered an alternative [9–11]. Several studies have been conducted 70 to evaluate treatments that could safely reduce high Loa loa microfilaremia, thereby making populations eligible 71 for IVM treatment. Different albendazole (ALB) regimens were tested using various designs. In Cameroon, 72 administering ALB 400 mg for three days showed a reduction in microfilaremia at day 90 [12]. When patients 73 with high Loa loa microfilaremia were given two or six doses of ALB 800 mg every two months, a decrease in 74 microfilaremia was observed in patients receiving six doses after four months [13]. Recently in Gabon, a five-75 week regimen of ALB 400 mg showed a reduction in microfilaremia comparable to a treatment with ALB 400 mg 76 for three weeks coupled with IVM [14]. Since the conclusion of the onchocerciasis control program activities in 77 Gabon, IVM is not readily accessible to physicians and their patients. On one hand, these studies highlight the microfilaricidal effect of ALB; on the other hand, they underscore the lack of a standardized protocol for treating 78 79 microfilaremic loiasis.

A significant body of research suggests that loiasis should be regarded as a major health issue [15,16]. Most loiasis patients have low microfilaremia (< 8000 mf/mL) and reside in rural areas [17,18]. In these regions, rural communities primarily access ALB through local dispensaries, which are their main healthcare facilities. The local populations primarily engage in agriculture, fishing and hunting, which generally do not provide substantial income. Clinically, low or absent microfilaremia is often associated with frequent symptoms such as Calabar

- 85 swellings [4]. It would be beneficial for these populations to assess whether ALB, an inexpensive medication,
- 86 could be used for curative purposes in patients with low microfilaremia as an alternative to IVM.
- 87 Therefore, the aim of this study was to evaluate the efficacy and safety of 400 mg dose of ALB compared to IVM
- 88 for treating infected patients in Gabon.
- 89

# 90 Material and methods

### 91 Study sites and population

This survey was conducted among the rural populations of Woleu-Ntem, specifically in the departments of Ntem and Haut Ntem. Woleu-Ntem is a province located in the northern region of Gabon, a Central African country. The province has an equatorial climate characterized by hot, humid conditions and high rainfall. It is covered with old secondary forests and has rich and varied wildlife [19]. In Woleu-Ntem, the overall prevalence of *Loa loa* is 20.2%. The rural populations live along roads and rivers, with farming being their primary activity. Fishing and hunting are also common, which increases their exposure to Chrysops bites, the vectors responsible for transmitting *Loa loa* [20].

99

#### 100 Study design

101 This survey is a non-inferiority randomized control trial aimed at evaluating the efficacy and safety of a 400 mg 102 dose of ALB taken daily for 30 days versus a single dose of IVM at 200µg/kg. The study was conducted from 103 November 7, 2021, to April 1, 2022, in thirty-four villages within the province of Woleu-Ntem, located in northern 104 Gabon. A preliminary visit was made to inform local authorities about the study's purpose. After obtaining 105 informed consent, participants' sociodemographic and clinical data were collected. This included information on 106 the study site, participant identification, age, sex, weight, height, and clinical symptoms related to loiasis, such as 107 worm migration into the eye, Calabar swelling, adult worm migration under the skin, and pruritus.

108

#### 109 Inclusion criteria

110 Eligible participants were individuals aged 18 to 75 years who were diagnosed with Loa loa infection confirmed

111 by microscopy, with microfilarial counts ranging from  $\geq$ 500 to  $\leq$ 3500 mf/mL.

112

#### 113 Exclusion criteria

114 Participants were excluded if they had acute systemic illnesses, suspected allergies to benzimidazoles, or were

115 pregnant or nursing.

116

#### 117 Blood collection and microfilaremic loiasis diagnosis

118 Venous blood was collected in an EDTA tube for parasitological diagnosis. A 10 µL blood sample was examined
119 directly, and the leukoconcentration technique, as described by Ho Thi Sang and Petithory, was performed [21].
120 Microfilaremia was quantified as the number of microfilariae per milliliter of blood (mf/mL). Absence of
121 microfilaremia was defined as the absence of detectable parasites following both microscopic techniques.

122

#### 123 Eosinophil count

Eosinophils were counted from a thin blood smear prepared from a 5  $\mu$ l sample. The count was expressed as a percentage based on 100 white blood cells observed under a light microscope. A count of  $\geq$  7% was considered indicative of hypereosinophilia.

127

### 128 Randomization and treatment procedure

Individuals were randomly assigned to one of two treatment groups following stratification based on three levels of *Loa loa* microfilaremia: 500—1500; 1501—2500; 2501—3500 mf/ml, taking into account age, gender, and the level of microfilaremia. Treatment was administered as follows: patients either received a daily dose of one tablet of ALB (400 mg) for 30 days or a single calculated dose of IVM (200µg/kg) based on the patient's weight. Both treatments were supplemented with 3 mg of antihistaminic-H2 daily for 7 days. Blood samples were collected before treatment initiation, and subsequently on days 2, 7, 14, and 30, to monitor microfilarial load and eosinophilia throughout the follow-up period.

### 137 Monitoring of clinical signs and adverse events

138 Adverse events were systematically evaluated throughout the study and categorized by severity: mild if they caused

139 minimal discomfort and did not disrupt daily activities, moderate if they interfered with daily activities to a

140 noticeable extent, and severe if they significantly impaired the patient's ability to carry out normal daily tasks.

141

### 142 Efficacy assessments

Blood samples for direct examination (10 µL) and leukoconcentration were collected at baseline, prior to administration of the study drug, and on days 2, 7, 14, and 30 to assess microfilarial load. Given the diurnal periodicity of the filarial species, all efforts were made to collect blood samples between 10:00 am and 3:00 pm.

### 147 Monitoring of eosinophil count

148 Eosinophils were counted from a thin blood smear using 5 µl of blood. Blood smears were conducted at baseline,

prior to administration of the study drug, and on days 2, 7, 14, and 30 to assess the eosinophil levels.

150

#### 151 Ethical considerations

152 This study was conducted as part of the PHYLECOG project funded by the EDCTP2 program under reference 153 TMA2019CDF-2730. The study protocol was reviewed and approved by the National Ethics Committee for 154 Scientific Research. Written informed consent was obtained from each participant after explaining the study 155 (Protocol No. 0053/2022/CNER/P/SG). The study is registered under ISRCTN14889921.

156

### 157 **Outcomes/Endpoints**

158 The primary endpoint of this study was the reduction rate of microfilaremia. Non-inferiority between a monthly

- 159 course of ALB and a single course of IVM was assessed based on the difference in reduction rates.
- 160 Treatment with ivermectin for microfilaremic loiasis typically results in rapid and sustained reduction, achieving
- a reduction rate of approximately 90% after 30 days, whereas placebo generally achieves a 50% reduction [22,23].

162 To establish non-inferiority, a margin of 20% was selected using the fixed margin method, which is half the

163 difference in reduction rates observed between ivermectin and placebo.

164 The investigator monitored adverse events, categorizing them by type and severity. The primary safety endpoint

165 was the occurrence of any adverse event following treatment initiation, regardless of its relationship to the study

drug. The secondary safety endpoint involved tracking the evolution of eosinophil levels throughout the treatment

167 period.

168

#### 169 Sample size

170 Based on an expected 73% reduction in microfilaremia with ALB and a 90% reduction with IVM [22–24], and

assuming a first-species risk of 5.0% and a second-species risk of 10.0%, with a non-inferiority margin of 20%, it

172 was determined that a minimum of 18 patients per group would be required for this study.

173

#### 174 Statistical analysis

Data processing was conducted using Microsoft Excel 2016, overseen by both an operator and a checker. Rsoftware version 4.3.0 was utilized for comprehensive data analysis.

177 Statistical analyses adhered to the principles outlined in the Consort 2010 statement, employing both per-protocol 178 and intention-to-treat methodologies [25]. The per-protocol analysis focused exclusively on patients who 179 completed their prescribed treatment regimen. Conversely, the intention-to-treat analysis included all randomized 180 patients, irrespective of treatment completion.

181 Categorical data such as sex, symptoms, and adverse events were summarized as absolute values and percentages.

182 These were compared using the proportion test, given the sample size was less than thirty, which is suitable for183 such analyses.

184 Continuous variables were evaluated for normality. Variables following a normal distribution, such as age, weight,

height, BMI, and microfilaremia, were presented as mean ± standard deviation. Variables not following a normal

distribution, like the eosinophil rate, were presented as median [1st percentile - 3rd percentile].

187 The reduction rate in microfilaremia was calculated as a percentage using the formula: ((Microfilaremia at D0 -

188 Microfilaremia during follow-up) / Microfilaremia at D0) \* 100.

- 189 Comparisons of microfilaremia or eosinophil rate between different time points were conducted using Student's t-
- 190 test for normally distributed variables or the Wilcoxon signed rank test for variables with non-normal distribution.

191

# 192 **Results**

### 193 Patients

- 194 Among the 1363 registered patients, 21 were excluded, leaving 1342 participants eligible for the study. Of these,
- 406 (30.2%) presented with Loa loa microfilaremia. Ultimately, 48 patients were enrolled, with 24 receiving ALB
- and 24 receiving IVM. However, during the follow-up period, 10 patients withdrew their consent (Fig 1).



197 Fig. 1. Study flowchart. \* Refusal of venipuncture; \*\* Long-term traveler; not visited: could not be collected at
198 the appropriate times for microfilaremia assessment, but present at the following visit.

#### **Demographic and baseline characteristics** 199

200 The characteristics of the study population are summarized in Table 1. There were no significant differences

201 between the two groups of patients (p > 0.05) in terms of sex, age, weight, height, microfilaremia, and eosinophil

202 rate.

203 Table 1. Descriptive characteristics of the two treatment groups at the inclusion (	1 (DU)
---	--------

	ALBENDAZOLE (n=22)	IVERMECTIN (n=24)	<i>p</i> -
	n (%)	n (%)	value
Male	17 (70.8)	10 (41.7)	0.08
	Mean ± SD or	Mean $\pm$ SD or	
	median [1 <sup>st</sup> percentile - 3 <sup>rd</sup> percentile]	median [1 <sup>st</sup> percentile - 3 <sup>rd</sup> percentile]	
Age (years)	49.8±12.5	53.0±13.6	0.4
Weight (Kg)	64.3±10.3	64.5±10.7	0.9
Height (m)	1.6±0.1	1.6±0.1	0.2
BMI (Kg/m <sup>2</sup> )	23.6±3.2	24.6±4.2	0.4
Microfilaremia (mf/mL)	1150 [700 - 1625]	1350 [875 - 2000]	0.5
Eosinophil rate (%)	16.0 [10.5 - 21.0]	16.0 [12.5 - 25.5]	0.5

204 SD: standard deviation

205

#### **Per-protocol analysis** 206

#### Efficacy of treatments on the reduction of microfilaremia 207

208 Both treatment groups showed significant reductions in mean microfilaremia from day 0 to day 30. Specifically,

209 the ALB group exhibited a reduction of 82.3% (1339 to 237 mf/ml), while the IVM group showed a reduction of

210 90.4% (1395 to 134 mf/ml) (p < 0.001) (Fig 2.a). The risk difference between the two treatments was 8.1% [95%

211 CI: 16.8; -0.6%], and the 95% confidence interval did not exceed the margin of non-inferiority.





213 Fig 2.a. Comparison of the albendazole and ivermectin parasitological cure rate (Per-protocol). The blue 214 line on the chart represents the microfilaremia levels of patients treated with albendazole, while the pink line 215 represents those treated with ivermectin.

216

#### Intention-to-treat analysis and secondary outcomes 217

#### Efficacy of treatments on the reduction of microfilaremia 218

- 219 The mean microfilaremia in patients from both treatment groups decreased significantly by 82.4% (1350 to 237
- 220 mf/ml) and 90.8% (1454 to 134 mf/ml) from day 0 to day 30 in the ALB and IVM groups, respectively (p < 0.001)

- (Fig 2.b). The risk difference between the two treatments was 8.4% [95% CI: 16.5; 0.7%], and the 95% confidence
- interval did not exceed the margin of non-inferiority.



223

Fig 2.b. Comparison of the albendazole and ivermectin parasitological cure rate (Intention-to-treat). In this
line chart, the blue line represents the microfilaremia levels of patients treated with albendazole, while the pink
line represents those treated with ivermectin.

#### 228 Incidence and progression of adverse events and symptoms during treatment

At baseline, approximately half of the patients in both groups reported symptoms: 41.7% (n=10) in the ALB group and 54.2% (n=13) in the IVM group (p=0.6). The most frequent symptom was pruritus, noted in 90.0% (n=9/10) of patients in the ALB group and 69.2% (n=9/13) in the IVM group. Over the course of follow-up, the number of patients experiencing symptoms decreased, with no patients reporting symptoms by day 30 in either group (Fig 3.a).

In terms of adverse events, a total of 10 patients (41.7%) in the ALB group and 8 patients (33.3%) in the IVM group reported adverse events by day 2 (p=0.8) (Fig 3.b). The most common adverse event in the ALB group was asthenia, reported by 80.0% (n=8/10) of those experiencing adverse events, followed by increased appetite in 20.0% (n=2/10). In the IVM group, the most common adverse events were asthenia, reported by 50.0% (n=4/8), and headache, reported by 25.0% (n=2/8) (Fig 3.b).



239

Fig 3.a. Changes in clinical signs and adverse events over the 30-day follow-up period. The histogram shows
adult worms in the eye with blue bars, adverse events with yellow bars, Calabar swelling with red bars, crawling
sensation with green bars, and pruritus with purple bars.



244 Fig 3.b. Changes in clinical adverse events over the 30-day follow-up period. The histogram shows appetite 245 disorders with pink bars, asthenia with dark gold bars, diarrhea with an aquamarine bar, headache and/or vertigo 246 with maroon bars, and nausea with a chartreuse green bar.

247

#### Efficacy of treatments on eosinophil level reduction 248

249 In both groups, eosinophil rates decreased by Day 30, although the difference was not statistically significant (p > 1250 0.05). In the albendazole group, eosinophil rates initially increased from Day 0 to Day 2, followed by a decline 251 across subsequent visits, reducing from a median rate of 16% to 7% (Fig 8). Conversely, in the ivermectin group, 252 eosinophil rates remained stable from Day 0 to Day 14, with a decrease observed by Day 30 from a median rate 253 of 16% to 4% (Fig 4).

medRxiv preprint doi: https://doi.org/10.1101/2024.08.16.24310835; this version posted August 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .



Fig 4. Eosinophil rate progression by treatment. The blue line on the chart depicts the eosinophil rate of patients
treated with albendazole, while the pink line represents those treated with ivermectin.

256

### 257 **Discussion**

This clinical trial represents the first comparison of a 30-day treatment regimen with ALB and IVM. The primary objective was to evaluate ALB's efficacy and safety as a potential non-inferior alternative to IVM. This is particularly relevant for landlocked rural populations who may have easier access to ALB than IVM.

261 In the intention-to-treat analysis of this trial, patients in both the ALB and IVM groups experienced a significant

262 decrease in mean microfilaremia from day 0 to day 30. The reduction was more pronounced among those treated

with IVM, with a risk difference of 8.6%. However, the 95% confidence interval for this difference did not reach

- or exceed the non-inferiority margin of 20%. These results confirm the non-inferiority of monthly ALB treatment
- compared to IVM.
- For the per-protocol analysis, the same trend was observed. Patients' mean microfilaremia significantly decreased from day 0 to day 30 in both the ALB and IVM groups. The reduction was more pronounced in patients treated with IVM, with a risk difference of 8.1%. However, the 95% confidence interval for this risk difference did not exceed the non-inferiority margin of 20%, confirming the non-inferiority of monthly ALB treatment compared to IVM.
- 271

During the follow-up, the number of patients with symptoms decreased, and no patient exhibited any loiasis symptoms by day 30 in either group. This highlights an adequate clinical response to both treatments. However, these findings contrast with the results of the retrospective observational study by Gobbi et al., where 31.3% of patients treated with a single dose of IVM and 50% of those treated with ALB (400 mg/day) were still symptomatic after 30 days of treatment [26].

277 Less than half of the patients in both treatment groups experienced adverse events during the follow-up period, 278 with asthenia being the most common in both groups. The frequency of these adverse events decreased over 279 subsequent visits, indicating the treatments' safety, all of which were mild. Similar findings have been reported in 280 prior studies using comparable dosages, where no participants experienced serious adverse events [26,27].

Regarding the impact of both treatments on eosinophil counts, there was no statistically significant reduction observed in either treatment group during the follow-up period. These results are consistent with Herrick et al., who found no decrease in eosinophil rates after two weeks of IVM treatment [28]. They also align with Klion et al., who reported no reduction in eosinophil rates after 21 days of ALB treatment [24]. However, despite the lack of significant decrease over the 30-day treatment period, there appeared to be a negative correlation between treatment duration and eosinophil rates.

287 These findings suggest that monthly treatment with ALB could serve as a viable alternative for rural populations 288 lacking easy access to IVM and limited financial resources. The study's strengths include its randomized design, 289 prospective registration, and comprehensive analysis employing both per-protocol and intention-to-treat methods. 290 However, the study also had its limitations. Firstly, due to the nature of the treatments, blinding was not feasible. 291 Additionally, being a non-inferiority study focused on comparing microfilaremia reduction rates between 292 treatments, it had inherent constraints in assessing other potential clinical endpoints.

293

# 294 Conclusion

295 The prevalence of *Loa loa* infection is notably high in the investigated villages of the Woleu-Ntem province, 296 Gabon. While IVM treatment exhibited a more pronounced microfilaricidal effect, the difference in risk between 297 the two treatments, as indicated by the associated 95% confidence interval, did not exceed the margin of inferiority. 298 This confirms the non-inferiority of ALB treatment. Moreover, ALB treatment demonstrated an adequate clinical

response and exhibited good safety profiles similar to IVM.

# 301 Acknowledgments

The authors extend their sincere gratitude to all the staff at the Centre de Recherche biomédicale En pathogènes Infectieux et Pathologies Associées (CREIPA) and the Unité Mixte de Recherche sur les Agents Infectieux et leur Pathologie (UMRAIP) for their invaluable support in participant recruitment in Bitam, and for their assistance with sample analysis in both Libreville and Bitam. Special thanks are also due to the management of the Bifolossi Medical Center for generously hosting our study. We extend our appreciation to the village chiefs and other relevant authorities for their unwavering support throughout this research. Finally, heartfelt thanks to all the participants whose cooperation made this study possible.

309

# **310** Author contributions

- 311 Conceptualization: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet, Noé Patrick
   212 M'Pondoukué
- 312 M'Bondoukwé
- 313 Data curation: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé
- 314 Formal analysis: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé
- 315 Funding acquisition: Marielle Karine Bouyou Akotet, Noé Patrick M'Bondoukwé
- 316 Investigation: Luccheri Ndong Akomezoghe, Mérédith Flore Ada Mengome, Roger Hadry Sibi Matotou, Bridy
- 317 Chesly Moutombi Ditombi, Valentin Migueba, Jacques Mari Ndong Ngomo, Noé Patrick M'Bondoukwé
- 318 Methodology: Luccheri Ndong Akomezoghe, Denise Patricia Mawili-Mboumba, Noé Patrick M'Bondoukwé
- 319 Project administration: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet
- 320 Resources: Marielle Karine Bouyou Akotet
- 321 Supervision: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet
- 322 Validation: Denise Patricia Mawili-Mboumba, Marielle Karine Bouyou Akotet
- 323 Visualization: Luccheri Ndong Akomezoghe
- 324 Writing-original draft: Luccheri Ndong Akomezoghe, Noé Patrick M'Bondoukwé, Denise Patricia Mawili-
- 325 Mboumba
- 326 Writing-review and editing: Luccheri Ndong Akomezoghe, Marielle Karine Bouyou Akotet, Denise Patricia
- 327 Mawili-Mboumba, Noé Patrick M'Bondoukwé

# 329 **References**

330	1.	Wanji S, Chounna Ndongmo WP, Fombad FF, Kengne-Ouafo JA, Njouendou AJ, Longang
331		Tchounkeu YF, et al. Impact of repeated annual community directed treatment with ivermectin
332		on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and
333		lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa. PLoS Negl Trop
334		Dis. 2018;12(9):1–24.
335	2.	Gobbi F, Buonfrate D, Boussinesq M, Chesnais CB, Pion SD, Silva R, et al. Performance of
336		two serodiagnostic tests for loiasis in a non-endemic area. PLoS Negl Trop Dis [Internet].
337		2020;14(5):1–11. Available from: http://dx.doi.org/10.1371/journal.pntd.0008187
338	3.	Bouyou Akotet MK, Owono-Medang M, Mawili-Mboumba DP, Moussavou-Boussougou MN,
339		Nzenze Afène S, Kendjo E, et al. The relationship between microfilaraemic and
340		amicrofilaraemic loiasis involving co-infection with Mansonella perstans and clinical
341		symptoms in an exposed population from Gabon. J Helminthol. 2016;90(4):469-75.
342	4.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M,
342 343	4.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese
342 343 344	4.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from:
342 343 344 345	4.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from: http://dx.doi.org/10.1016/j.actatropica.2013.11.012
342 343 344 345 346	4. 5.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from: http://dx.doi.org/10.1016/j.actatropica.2013.11.012 Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp
<ul> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> <li>347</li> </ul>	4. 5.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from: http://dx.doi.org/10.1016/j.actatropica.2013.11.012 Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp Quimioter. 2016;29(6):288–95.
<ul> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> <li>347</li> <li>348</li> </ul>	4. 5. 6.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M, Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from: http://dx.doi.org/10.1016/j.actatropica.2013.11.012 Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp Quimioter. 2016;29(6):288–95. Carme B, Esterre P. Filarioses. EMC - Mal Infect. 2012;9(2):1–19.
<ul> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> <li>347</li> <li>348</li> <li>349</li> </ul>	4. 5. 6. 7.	<ul> <li>Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M,</li> <li>Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese</li> <li>patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from:</li> <li>http://dx.doi.org/10.1016/j.actatropica.2013.11.012</li> <li>Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp</li> <li>Quimioter. 2016;29(6):288–95.</li> <li>Carme B, Esterre P. Filarioses. EMC - Mal Infect. 2012;9(2):1–19.</li> <li>Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.</li> </ul>
<ul> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> <li>347</li> <li>348</li> <li>349</li> <li>350</li> </ul>	4. 5. 6. 7.	Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M,Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonesepatients co-infected with Loa Ioa. Acta Trop [Internet]. 2014;131(1):11–5. Available from:http://dx.doi.org/10.1016/j.actatropica.2013.11.012Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev EspQuimioter. 2016;29(6):288–95.Carme B, Esterre P. Filarioses. EMC - Mal Infect. 2012;9(2):1–19.Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for
<ul> <li>342</li> <li>343</li> <li>344</li> <li>345</li> <li>346</li> <li>347</li> <li>348</li> <li>349</li> <li>350</li> <li>351</li> </ul>	<ol> <li>4.</li> <li>5.</li> <li>6.</li> <li>7.</li> </ol>	<ul> <li>Bouyou-Akotet MK, Moussavou Boussougou MN, Ovono-Abessolo F, Owono-Medang M,</li> <li>Kombila M. Influence of Mansonella perstans microfilaraemia on total IgE levels in Gabonese</li> <li>patients co-infected with Loa loa. Acta Trop [Internet]. 2014;131(1):11–5. Available from:</li> <li>http://dx.doi.org/10.1016/j.actatropica.2013.11.012</li> <li>Cobo F. Determinants of parasite drug resistance in human lymphatic filariasis. Rev Esp</li> <li>Quimioter. 2016;29(6):288–95.</li> <li>Carme B, Esterre P. Filarioses. EMC - Mal Infect. 2012;9(2):1–19.</li> <li>Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.</li> <li>Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for</li> <li>Loa loa infection. Lancet. 1997;350(9070):18–22.</li> </ul>

after single-dose diethylcarbamazine or ivermectin in subjects with Loa Loa infection. Clin

354 Infect Dis. 2017;64(8):1017–25.

- Ella SN, Ogoussan K, Gass K, Hundley L, Diggle PJ, Johnson O, et al. An Integrated District
   Mapping Strategy for Loiasis to Enable Safe Mass Treatment for Onchocerciasis in Gabon. Am
   J Trop Med Hyg. 2022;106(2):732–9.
- 358 10. Zouré HGM, Noma M, Tekle AH, Amazigo U V., Diggle PJ, Giorgi E, et al. The geographic
  359 distribution of onchocerciasis in the 20 participating countries of the African Programme for
  360 Onchocerciasis Control: (2) pre-control endemicity levels and estimated number infected.
  361 Parasites and Vectors. 2014;7(1):1–15.
- 11. Kamgno J, Nana-Djeunga HC, Pion SD, Chesnais CB, Klion AD, Mackenzie CD, et al.

363 Operationalization of the test and not treat strategy to accelerate the elimination of

364 onchocerciasis and lymphatic filariasis in Central Africa. Int Health. 2018;10(March):i49–53.

- Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, et al. Human loiasis
  in a Cameroonian village: A double-blind, placebo-controlled, crossover clinical trial of a
  three-day albendazole regimen. Am J Trop Med Hyg. 2004;71(2):211–5.
- 13. Kamgno J, Nguipdop-Djomo P, Gounoue R, Téjiokem M, Kuesel AC. Effect of Two or Six

369 Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double

Blind, Randomized, Placebo-Controlled Trial. PLoS Negl Trop Dis. 2016;10(3):1–19.

14. Zoleko-Manego R, Kreuzmair R, Veletzky L, Ndzebe-Ndoumba W, Ekoka Mbassi D, Okwu

372 DG, et al. Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for

the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled

- assessor blinded clinical trial. PLoS Negl Trop Dis. 2023;17(8):e0011584.
- Buell KG, Whittaker C, Chesnais CB, Jewell PD, Pion SDS, Walker M, et al. Atypical Clinical
  Manifestations of Loiasis and Their Relevance for Endemic Populations. Open Forum Infect
  Dis. 2019;6(11):1–9.

378 16. Id LV, Eberhardt KA, Hergeth J, Stelzl R, Manego RZ, Mombo-ngoma G, et al. Distinct loiasis

379	infection states and associated clinical and hematological manifestations in patients from
380	Gabon. 2022;1–15.

- 381 17. Mogoung-Wafo AE, Nana-Djeunga HC, Domche A, Fossuo-Thotchum F, Bopda J,
- 382 Mbickmen-Tchana S, et al. Prevalence and intensity of Loa loa infection over twenty-three
- 383 years in three communities of the Mbalmayo health district (Central Cameroon). BMC Infect
- 384 Dis. 2019;19(1):1–7.
- 385 18. Mischlinger J, Manego RZ, Id GM ngoma, Ekoka D, Id M, Hackbarth N, et al. PLOS

386 NEGLECTED TROPICAL DISEASES Diagnostic performance of capillary and venous blood

387 samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light
388 microscopy. 2021;1–12.

- Ngoua-Meye-Misso RL, Sima-Obiang C, Ndong JDLC, Ndong-Atome GR, Ondo JP, Ovono
  Abessolo F, et al. Medicinal plants used in management of cancer and other related diseases in
  Woleu-Ntem province, Gabon. Eur J Integr Med [Internet]. 2019;29(May):100924. Available
  from: https://doi.org/10.1016/j.eujim.2019.05.010
- Akue JP, Nkoghe D, Padilla C, Moussavou G, Moukana H, Mbou RA, et al. Epidemiology of
  Concomitant Infection Due to Loa loa and Mansonella perstans in Gabon. 2011;5(10).
- 395 21. Ho Thi Sang, Petithory J. Techniques for the Concentration of Microfilariae from the Blood.
  396 Bull la Soc Pathol Exot. 1963;56(2):197–206.

39722.Pion SD, Tchatchueng-Mbougua JB, Chesnais CB, Kamgno J, Gardon J, Chippaux JP, et al.

398 Effect of a single standard dose (150-200  $\mu$ g/kg) of ivermectin on loa loa microfilaremia:

- 399 Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019;6(4):1–18.
- 400 23. Kamgno J, Pion SDS, Tejiokem MC, Twum-Danso NAY, Thylefors B, Boussinesq M.
- 401 Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia:
- 402 efficacy of a low dose ( $\sim$ 25 µg/kg) versus current standard dose (150 µg/kg). Trans R Soc Trop
- 403 Med Hyg. 2007;101(8):777–85.

404	24.	Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, et al.
405		Albendazole in Human Loiasis: Results of a Double-Blind, Placebo-Controlled Trial. J Infect
406		Dis. 1993;168(1):202–6.
407	25.	Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. Reporting of Noninferiority and
408		Equivalence Randomized Trials Extension of the CONSORT 2010 Statement. 2012;
409	26.	Gobbi F, Bottieau E, Bouchaud O, Buonfrate D, Salvador F, Rojo-Marcos G, et al. Comparison
410		of different drug regimens for the treatment of loiasis-A TropNet retrospective study. PLoS
411		Negl Trop Dis. 2018;12(11):1–11.
412	27.	Bouchaud O, Matheron S, Loarec A, Dupouy Camet J, Bourée P, Godineau N, et al. Imported
413		loiasis in France: A retrospective analysis of 167 cases with comparison between sub-Saharan
414		and non sub-Saharan African patients. BMC Infect Dis. 2020;20(1):1-7.
415	28.	Herrick JA, Metenou S, Makiya MA, Taylar-Williams CA, Law MA, Klion AD, et al.
416		Eosinophil-associated processes underlie differences in clinical presentation of loiasis between
417		temporary residents and those indigenous to loa-endemic areas. Clin Infect Dis. 2015;60(1):55-
418		63.